Johnson & Johnson Faces 67,500 Lawsuits as Judge Allows Expert Testimony
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy JNJ?
Source: Yahoo Finance
- Litigation Progress: A federal judge ruled that plaintiffs in over 67,500 lawsuits against Johnson & Johnson regarding baby powder and talc products can present expert testimony at trial, marking a significant step towards trial proceedings.
- Scientific Evidence Review: The judge aims to reevaluate scientific evidence due to changes in federal rules and the emergence of new evidence, which could significantly impact the validity of expert testimonies and the overall case outcomes.
- Historical Verdicts Overview: Johnson & Johnson has faced jury awards as high as $4.69 billion in state court cases, highlighting the legal risks and potential financial burdens associated with talc-related litigation.
- Bankruptcy Strategy Failure: Johnson & Johnson's attempts to resolve litigation through bankruptcy were rejected three times by federal courts, resulting in the suspension of most cases and illustrating the challenges the company faces in its legal battles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 230.750
Low
190.00
Averages
218.50
High
240.00
Current: 230.750
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson to Present at Health Care Conference
- Conference Schedule: Johnson & Johnson will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, with management engaging in a Fireside Chat at 11:10 a.m. Eastern Time, showcasing the company's latest developments in the healthcare sector.
- Live Webcast Availability: The presentation will be accessible via Johnson & Johnson's Investor Relations website, ensuring that investors and the public can obtain real-time information about the company, thereby enhancing transparency and communication efficiency.
- Replay Arrangement: An archived version of the session will be available later that day, allowing investors who could not listen live to review the important information, further improving accessibility to corporate communications.
- Replay Timing: The audio webcast replay will be available approximately 48 hours after the live event, ensuring that investors can access critical information at their convenience, reflecting the company's commitment to investor relations.
See More
Johnson & Johnson to Present at Health Care Conference
- Conference Schedule: Johnson & Johnson will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, with management participating in a Fireside Chat at 11:10 a.m. Eastern Time, showcasing the company's latest developments in healthcare.
- Live Webcast Availability: The presentation will be accessible via Johnson & Johnson's Investor Relations website, ensuring global investors can obtain real-time company information, thereby enhancing transparency and investor confidence.
- Replay Arrangement: An archived version of the session will be available later that day, allowing investors who could not attend live to review the content, further increasing information accessibility.
- Media and Investor Contacts: Johnson & Johnson has provided contact emails for media and investor relations, ensuring timely access to relevant information and fostering communication and interaction with investors.
See More
FDA Launches Pilot PreCheck Program for Pharma Manufacturing
- PreCheck Program Launch: The US FDA has begun accepting applications for its PreCheck program aimed at simplifying the construction process for new pharmaceutical manufacturing facilities, thereby enhancing overall industry efficiency and responsiveness.
- Two-Phase Implementation: The program consists of two phases; the first phase, Facility Readiness, involves regular contact between manufacturers and the FDA for early technical advice to ensure smooth operations and pre-operational reviews.
- Priority for Critical Drugs: The FDA has stated that priority will be given to facilities producing innovative and critical medicines for the US market, which will help enhance the stability and safety of the domestic drug supply chain.
- Pharma Giants' Investments: Since President Trump took office in January 2025, major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and Merck, have agreed to make significant investments in US manufacturing facilities, reflecting the industry's commitment to bolstering domestic manufacturing capabilities.
See More
AbbVie's Outlook for the Next Five Years
- Significant Sales Growth: In the first nine months of 2025, combined sales of Skyrizi and Rinvoq reached approximately $15 billion, accounting for nearly 45% of AbbVie's total revenue, highlighting the critical role these drugs will play in the company's future finances.
- Strong Market Forecast: Analysts predict that by 2030, sales for Skyrizi and Rinvoq will reach at least $32 billion, further solidifying AbbVie's market position in immunology.
- Huge New Drug Potential: AbbVie's cancer therapy Elahere and Parkinson's drug Vyalev are expected to become new blockbusters within the next five years, potentially driving overall revenue growth for the company.
- Ongoing Dividend Growth: AbbVie has increased its dividend for 54 consecutive years and is expected to continue this trend, further boosting investor confidence and enhancing the company's value.
See More
Investment Opportunities in Consumer Staples Stocks for 2026
- Market Performance Review: The S&P 500 has gained 78.3% from 2023 to 2025, while the consumer staples sector has only increased by less than 5%, indicating a potential contrarian investment opportunity for value investors amid the sector's underperformance.
- Procter & Gamble's Situation: Procter & Gamble faced a 14.5% stock price decline in 2025, and despite a slight recovery in early 2026, a 1% drop in sales volume and a 5% decrease in net earnings highlight significant challenges, with future growth expectations remaining weak.
- Kimberly-Clark's Acquisition Plan: Kimberly-Clark anticipates achieving $2.1 billion in annual cost synergies from its acquisition of Kenvue, and while short-term performance is lackluster, this strategy may provide better growth prospects in the long run, attracting value investors' interest.
- Dividend Appeal: Procter & Gamble and Kimberly-Clark offer dividend yields of 2.9% and 5%, respectively, with both companies having a long history of increasing dividends, providing stable cash flow for income-seeking investors despite market pressures.
See More
Market Outlook for Procter & Gamble and Kimberly-Clark
- Sales Strategy Shift: Procter & Gamble is focusing on increasing sales volumes rather than raising prices, despite a 14.5% stock decline in 2025; under new CEO leadership, the company aims to improve performance through volume growth, although it may face margin compression in the short term.
- Poor Financial Performance: P&G's Q2 report indicated a 1% decline in sales volume and flat organic sales growth, with 2026 EPS growth projected at only 1% to 6%, highlighting significant challenges in a weak demand environment.
- Kimberly-Clark's Acquisition Plans: Kimberly-Clark plans to diversify through the acquisition of Kenvue, expecting EPS growth within two years post-acquisition and $2.1 billion in annual cost synergies within three years, despite low near-term performance expectations.
- Dividend Appeal: Both P&G and Kimberly-Clark are attractive high-dividend stocks, with P&G yielding 2.9% and Kimberly-Clark at 5%, both having consistently increased dividends over the years, appealing to investors seeking passive income.
See More
Johnson & Johnson to Present at Health Care Conference
- Conference Schedule: Johnson & Johnson will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, with management engaging in a Fireside Chat at 11:10 a.m. Eastern Time, showcasing the company's latest developments in the healthcare sector.
- Live Webcast Availability: The presentation will be accessible via Johnson & Johnson's Investor Relations website, ensuring that investors and the public can obtain real-time information about the company, thereby enhancing transparency and communication efficiency.
- Replay Arrangement: An archived version of the session will be available later that day, allowing investors who could not listen live to review the important information, further improving accessibility to corporate communications.
- Replay Timing: The audio webcast replay will be available approximately 48 hours after the live event, ensuring that investors can access critical information at their convenience, reflecting the company's commitment to investor relations.
See More
Johnson & Johnson to Present at Health Care Conference
- Conference Schedule: Johnson & Johnson will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, with management participating in a Fireside Chat at 11:10 a.m. Eastern Time, showcasing the company's latest developments in healthcare.
- Live Webcast Availability: The presentation will be accessible via Johnson & Johnson's Investor Relations website, ensuring global investors can obtain real-time company information, thereby enhancing transparency and investor confidence.
- Replay Arrangement: An archived version of the session will be available later that day, allowing investors who could not attend live to review the content, further increasing information accessibility.
- Media and Investor Contacts: Johnson & Johnson has provided contact emails for media and investor relations, ensuring timely access to relevant information and fostering communication and interaction with investors.
See More
FDA Launches Pilot PreCheck Program for Pharma Manufacturing
- PreCheck Program Launch: The US FDA has begun accepting applications for its PreCheck program aimed at simplifying the construction process for new pharmaceutical manufacturing facilities, thereby enhancing overall industry efficiency and responsiveness.
- Two-Phase Implementation: The program consists of two phases; the first phase, Facility Readiness, involves regular contact between manufacturers and the FDA for early technical advice to ensure smooth operations and pre-operational reviews.
- Priority for Critical Drugs: The FDA has stated that priority will be given to facilities producing innovative and critical medicines for the US market, which will help enhance the stability and safety of the domestic drug supply chain.
- Pharma Giants' Investments: Since President Trump took office in January 2025, major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and Merck, have agreed to make significant investments in US manufacturing facilities, reflecting the industry's commitment to bolstering domestic manufacturing capabilities.
See More
AbbVie's Outlook for the Next Five Years
- Significant Sales Growth: In the first nine months of 2025, combined sales of Skyrizi and Rinvoq reached approximately $15 billion, accounting for nearly 45% of AbbVie's total revenue, highlighting the critical role these drugs will play in the company's future finances.
- Strong Market Forecast: Analysts predict that by 2030, sales for Skyrizi and Rinvoq will reach at least $32 billion, further solidifying AbbVie's market position in immunology.
- Huge New Drug Potential: AbbVie's cancer therapy Elahere and Parkinson's drug Vyalev are expected to become new blockbusters within the next five years, potentially driving overall revenue growth for the company.
- Ongoing Dividend Growth: AbbVie has increased its dividend for 54 consecutive years and is expected to continue this trend, further boosting investor confidence and enhancing the company's value.
See More
Investment Opportunities in Consumer Staples Stocks for 2026
- Market Performance Review: The S&P 500 has gained 78.3% from 2023 to 2025, while the consumer staples sector has only increased by less than 5%, indicating a potential contrarian investment opportunity for value investors amid the sector's underperformance.
- Procter & Gamble's Situation: Procter & Gamble faced a 14.5% stock price decline in 2025, and despite a slight recovery in early 2026, a 1% drop in sales volume and a 5% decrease in net earnings highlight significant challenges, with future growth expectations remaining weak.
- Kimberly-Clark's Acquisition Plan: Kimberly-Clark anticipates achieving $2.1 billion in annual cost synergies from its acquisition of Kenvue, and while short-term performance is lackluster, this strategy may provide better growth prospects in the long run, attracting value investors' interest.
- Dividend Appeal: Procter & Gamble and Kimberly-Clark offer dividend yields of 2.9% and 5%, respectively, with both companies having a long history of increasing dividends, providing stable cash flow for income-seeking investors despite market pressures.
See More
Market Outlook for Procter & Gamble and Kimberly-Clark
- Sales Strategy Shift: Procter & Gamble is focusing on increasing sales volumes rather than raising prices, despite a 14.5% stock decline in 2025; under new CEO leadership, the company aims to improve performance through volume growth, although it may face margin compression in the short term.
- Poor Financial Performance: P&G's Q2 report indicated a 1% decline in sales volume and flat organic sales growth, with 2026 EPS growth projected at only 1% to 6%, highlighting significant challenges in a weak demand environment.
- Kimberly-Clark's Acquisition Plans: Kimberly-Clark plans to diversify through the acquisition of Kenvue, expecting EPS growth within two years post-acquisition and $2.1 billion in annual cost synergies within three years, despite low near-term performance expectations.
- Dividend Appeal: Both P&G and Kimberly-Clark are attractive high-dividend stocks, with P&G yielding 2.9% and Kimberly-Clark at 5%, both having consistently increased dividends over the years, appealing to investors seeking passive income.
See More
